Avadel Pharmaceuticals to Present at the 24th Annual Needham Healthcare Conference
Rhea-AI Summary
Avadel Pharmaceuticals (Nasdaq: AVDL) has announced its upcoming participation in the 24th Annual Needham Healthcare Conference. The company's management team will engage in a fireside chat scheduled for Tuesday, April 8 at 1:30 p.m. ET.
Investors and interested parties can access a live webcast of the presentation through Avadel's Investor Relations website at investors.avadel.com. The recorded session will remain available on the website for 90 days following the conference.
Positive
- None.
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, AVDL declined 4.09%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
DUBLIN, April 01, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that members of management will participate in a fireside chat at the 24th Annual Needham Healthcare Conference on Tuesday, April 8 at 1:30 p.m. ET.
A live webcast of the fireside chat, as well as an archived recording, will be available on Avadel’s Investor Relations website, investors.avadel.com, for 90 days following the conference.
About Avadel Pharmaceuticals plc
Avadel Pharmaceuticals plc (Nasdaq: AVDL) is a biopharmaceutical company focused on transforming medicines to transform lives. Our approach includes applying innovative solutions to the development of medications that address the challenges patients face with current treatment options. Avadel’s commercial product, LUMRYZ™, was approved by the U.S. Food & Drug Administration (FDA) as the first and only once-at-bedtime oxybate for the treatment of cataplexy or EDS in patients 7 years of age and older with narcolepsy. For more information, please visit www.avadel.com.
Investor Contact:
Austin Murtagh
Precision AQ
Austin.Murtagh@precisionAQ.com
(212) 698-8696
Media Contact:
Lesley Stanley
Real Chemistry
lestanley@realchemistry.com
(609) 273-3162